```html

Quondam Migraine (Familial Hemiplegic Migraine)

Overview

Quondam migraine is another name for familial hemiplegic migraine (FHM), a rare genetic subtype of migraine with aura. Unlike typical migraines, FHM produces temporary weakness or paralysis (hemiplegia) on one side of the body during an attack. The term “quondam” (Latin for “once”) reflects the episodic nature of the disorder – the neurological deficits appear only during attacks and resolve completely afterward.

• Who it affects: Individuals of any age, but most cases present in childhood or adolescence. Both males and females are affected, though some studies suggest a slight female predominance (≈55%).
• Prevalence: FHM is extremely uncommon, estimated at 0.01–0.02 % of the general population (≈1–2 per 10,000 people) [Mayo Clinic, 2023]. Because it clusters in families, certain ethnic groups have slightly higher rates.

Symptoms

The hallmark of FHM is a migraine attack that includes motor aura—usually unilateral weakness that can mimic a stroke. Because symptoms vary widely, a complete list helps patients recognize patterns.

Typical migraine features

• Pulsating or throbbing head pain lasting 4–72 hours.
• Unilateral location (often one side of the head).
• Photophobia (sensitivity to light).
• Phonophobia (sensitivity to sound).
• Nausea or vomiting.

Motor aura (hemiplegia)

• Sudden weakness or paralysis affecting the arm, leg, or facial muscles on one side.
• Weakness may be mild (slight clumsiness) or severe (complete temporary paralysis).
• Typically develops within minutes of the headache onset and can last from a few minutes to several days; most episodes resolve within 24 hours.

Other aura symptoms

• Visual disturbances: scintillating scotoma, zig‑zag lines, blind spots.
• Sensory aura: numbness, tingling (paresthesia) spreading from the hand upward.
• Speech/language changes: dysarthria, difficulty finding words (aphasia).
• Ataxia: loss of coordination, stumbling.
• Brainstem aura: vertigo, double vision, hearing changes.

Prodromal and post‑dromal signs

• Mood changes, yawning, neck stiffness, or food cravings occurring hours to days before an attack.
• Post‑attack fatigue, “migraine hangover,” and difficulty concentrating.

Causes and Risk Factors

FHM is primarily a **monogenic autosomal‑dominant** disorder, meaning a single defective gene from one parent can cause the condition. The three most common genes are:

1. CACNA1A – encodes the alpha‑1A subunit of P/Q‑type voltage‑gated calcium channels.
2. ATP1A2 – encodes the alpha‑2 subunit of Na⁺/K⁺‑ATPase, important for neuronal ion balance.
3. SCN1A – encodes the Nav1.1 sodium channel, also implicated in some forms of epilepsy.

Mutations disrupt neuronal excitability, leading to cortical spreading depression (the wave of depolarization that underlies migraine aura) and, in FHM, spread to motor cortex areas, producing temporary hemiplegia.

Risk factors

• Family history: A first‑degree relative with FHM or classic migraine with aura.
• Specific gene mutation: Presence of a pathogenic variant in CACNA1A, ATP1A2, or SCN1A.
• Female sex: Slightly higher incidence, possibly due to hormonal influences.
• Triggers common to all migraines: Sleep deprivation, stress, hormonal fluctuations, certain foods (e.g., aged cheese, chocolate), alcohol, bright lights, strong odors.

Diagnosis

Because FHM mimics stroke, an accurate diagnosis relies on careful clinical evaluation and targeted testing.

Clinical criteria (International Classification of Headache Disorders‑3)

• At least two migraine attacks with motor aura lasting ≥ 5 minutes.
• Motor aura must be accompanied by at least one other typical aura symptom (visual, sensory, or speech).
• Family history of similar attacks OR identification of a pathogenic gene mutation.
• Exclusion of other disorders that could cause transient hemiplegia (e.g., stroke, seizures).

Diagnostic tests

• Neuroimaging (MRI or CT): Performed during an acute attack to rule out stroke or structural lesions. May show transient cortical edema but is usually normal.
• Electroencephalogram (EEG): Helps exclude seizures if the presentation is atypical.
• Genetic testing: Targeted panel for CACNA1A, ATP1A2, SCN1A, and less common genes (e.g., PRRT2). Testing confirms the diagnosis in ~60‑70 % of families.
• Blood work: Routine labs (CBC, electrolytes) are not diagnostic but may be ordered to exclude metabolic causes of weakness.

Differential diagnosis

Conditions that can look like FHM include:

• Ischemic stroke or transient ischemic attack (TIA)
• Complex migraine (without motor aura)
• Epileptic seizures with post‑ictal paralysis (Todd’s paresis)
• Multiple sclerosis demyelinating attacks
• Metabolic encephalopathies (e.g., hypoglycemia)

Treatment Options

Management aims to abort acute attacks, prevent recurrences, and minimize disability. Because FHM is rare, most recommendations are extrapolated from classic migraine studies and case series.

Acute treatment

• Triptans (e.g., sumatriptan, rizatriptan): Effective for many migraineurs, but in FHM they should be used cautiously—some reports link triptans to worsening hemiplegia. Start with a low dose under physician supervision.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Ibuprofen 400‑600 mg or naproxen 500 mg can relieve headache pain.
• Anti‑emetics: Metoclopramide 10 mg IV/PO or prochlorperazine 5‑10 mg for nausea and vomiting.
• Intravenous magnesium sulfate (1–2 g over 15 min): May shorten aura duration; evidence is modest but low‑risk.
• Hospital observation: If there is diagnostic uncertainty with stroke, patients are often admitted for monitoring and neuro‑imaging.

Preventive (prophylactic) therapy

1. Calcium channel blockers (e.g., verapamil 240‑480 mg/day) – useful especially for CACNA1A mutations.
2. Beta‑blockers (e.g., propranolol 40‑160 mg/day) – first‑line for many migraine types.
3. Antiepileptic drugs:
   • Topiramate 25‑100 mg/day – reduces cortical spreading depression.
   • Valproic acid 500‑1500 mg/day – helpful for patients with comorbid epilepsy.
4. Antidepressants (venlafaxine 75‑150 mg/day) – beneficial when anxiety/depression coexist.
5. Monoclonal antibodies targeting CGRP or its receptor (erenumab, fremanezumab): Limited data for FHM, but early case reports are promising. Use only after standard options fail.

Procedural options

• Occipital nerve stimulation: Rarely considered for refractory cases; data are limited.
• Botulinum toxin A injections: Effective for chronic migraine, but specific benefit for FHM remains uncertain.

Lifestyle and non‑pharmacologic measures

• Maintaining regular sleep–wake cycles.
• Hydration (≥2 L water/day).
• Identifying and avoiding personal triggers (keep a migraine diary).
• Stress‑reduction techniques: mindfulness, progressive muscle relaxation, CBT.
• Regular aerobic exercise (30 minutes most days) – improves vascular tone.
• Dietary considerations: limit caffeine, processed foods, and tyramine‑rich cheeses.

Living with Quondam Migraine (Familial Hemiplegic Migraine)

Because attacks can be disabling, practical day‑to‑day strategies help maintain independence and quality of life.

Preparation kit

• List of acute medications (e.g., NSAID, triptan, anti‑emetic).
• Copy of emergency contact numbers and a brief description of the condition for first‑responders.
• Medical alert bracelet indicating “Familial Hemiplegic Migraine – risk of temporary paralysis.”

Work and school accommodations

• Notify employer/teachers about the condition; request flexibility for missed days.
• Consider a quiet workspace, dim lighting, and the ability to rest when aura begins.
• Arrange for a trusted colleague or family member to assist during severe attacks.

Driving safety

Never drive during an attack with motor weakness or visual aura. Keep a spare key with a trusted person and use ride‑share services when needed.

Emotional wellbeing

• Join support groups (e.g., Migraine Research Foundation, rare disease forums).
• Seek counseling if anxiety about attacks interferes with daily life.

Prevention

While genetics cannot be changed, modifiable risk factors can be addressed.

• Trigger diary: Record foods, sleep hours, stress levels, menstrual cycle, and weather changes.
• Consistent schedule: Eat meals at regular times, maintain a sleep window (7‑9 hours).
• Limit caffeine and alcohol: >300 mg caffeine or >2 drinks per day increase attack frequency in many patients.
• Stress management: Yoga, meditation, or biofeedback have level‑B evidence for migraine reduction.
• Supplements: Magnesium 400 mg nightly and riboflavin 400 mg daily are low‑risk and may lower attack frequency [Cleveland Clinic, 2022].
• Vaccinations: Prevent infections (e.g., influenza) that can precipitate attacks.

Complications

If untreated or poorly managed, FHM can lead to serious outcomes.

• Prolonged neurological deficits: Rare cases report hemiplegia lasting >7 days, increasing the risk of muscle atrophy.
• Stroke mimics: Misdiagnosis may delay appropriate stroke care.
• Psychiatric comorbidities: Chronic pain and disability raise the risk of depression and anxiety (up to 30 % in migraine cohorts).
• Medication overuse headache: Frequent use of acute drugs (>10 days/month) can lead to rebound headaches.
• Reduced quality of life: Studies show lower scores on the SF‑36 health survey compared with the general population [NIH, 2021].

When to Seek Emergency Care

For routine migraine attacks without the above red flags, contact your primary care physician or neurologist to adjust preventive therapy.

References

• Mayo Clinic. “Familial hemiplegic migraine.” 2023. link
• World Health Organization. “Headache disorders.” 2022. link
• National Institutes of Health. “Migraine: Diagnosis and Management.” 2021. link
• Cleveland Clinic. “Magnesium for Migraine Prevention.” 2022. link
• International Headache Society. “The International Classification of Headache Disorders, 3rd edition (ICHD‑3).” 2018.
• American Stroke Association. “When to Call 911 for a Possible Stroke.” 2023. link

```